The clinical utility of next-generation sequencing for bone and soft tissue sarcoma
- 22 October 2021
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (1) , 38-44
Abstract
Background: Sarcomas are a rare and heterogeneous tumor group composed of a variety of histologic subtypes. Targeted next-generation sequencing (NGS) of bone and soft tissue sarcomas is a nascent field with limited evidence for its use within clinical practice. Therefore, further research is needed to validate NGS in sarcoma and assess the clinical utility of these techniques with the hope of improving treatment options. Methods: Comprehensive molecular profiling with NGS was performed on 136 tumors (116 soft tissue, 20 bone) using two commercial vendors. Patient records were retrospectively reviewed, and the clinical impact of NGS-related findings were qualitatively analyzed to determine actionable mutations and number of changes in treatment. Results: The median age was 55.0 years (IQR 42–67 years), and most patients were non-metastatic at presentation (80.9%, n = 110). Prior to performing NGS, 72.1% (n = 98) were treated with a mean 1.1 ± 1.2 lines of systemic chemotherapy. NGS identified 341 putative alterations with at least one mutation present in 89.7% (n = 122) of samples. In a subset of 111 patients with available TMB data, 78.7% (n = 107) had a low (n = 64) contained clinically actionable alterations, and 12 patients had a change in medical treatment based on NGS. Those who underwent a treatment change all had metastatic or recurrent disease; three of these patients experienced a clinical benefit. Conclusion: Most bone and soft tissue sarcomas harbor at least one genetic alteration, and it appears a sizeable number of tumors contain mutations that are clinically actionable. While a change in treatment based off NGS-related findings occurred in 12 cases, three patients experienced a clinical benefit. Our data provide further proof-of-concept for NGS in sarcoma and suggest a clinical benefit may be observed in select patients.Keywords
This publication has 16 references indexed in Scilit:
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical TrialsJournal of Clinical Oncology, 2015
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcomaProceedings of the National Academy of Sciences, 2014
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark AnalysesClinical Cancer Research, 2014
- Soft Tissue Sarcomas2014
- Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric OsteosarcomaCell Reports, 2014
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialThe Lancet Oncology, 2014
- Evolving techniques for gene fusion detection in soft tissue tumoursHistopathology, 2013
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Trends in survival for patients with metastatic soft‐tissue sarcomaCancer, 2010
- Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.Journal of Clinical Oncology, 1995